Novo A/S
Latest statistics and disclosures from Novo Holdings A/S's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EWTX, BN, ASML, MIRM, MPLT, and represent 51.27% of Novo Holdings A/S's stock portfolio.
- Added to shares of these 4 stocks: XENE (+$28M), CRM (+$12M), MIRM (+$5.6M), BBOT.
- Started 1 new stock position in XENE.
- Reduced shares in these 10 stocks: ZBIO (-$53M), INSM (-$35M), ASML (-$25M), APGE (-$10M), ELVN (-$7.8M), VALN (-$7.8M), VRDN (-$7.4M), PCVX, CRNX, Io Biotech.
- Sold out of its positions in Io Biotech, INSM, ZBIO.
- Novo Holdings A/S was a net seller of stock by $-106M.
- Novo Holdings A/S has $1.2B in assets under management (AUM), dropping by -4.15%.
- Central Index Key (CIK): 0001388325
Tip: Access up to 7 years of quarterly data
Positions held by Novo A/S consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Novo Holdings A/S
Novo Holdings A/S holds 22 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | 13.7 | $169M | 5.4M | 31.50 |
|
|
| Brookfield Corp Cl A Ltd Vt Sh (BN) | 11.5 | $142M | 3.5M | 40.47 |
|
|
| Asml Holding N V N Y Registry Shs (ASML) | 10.2 | $125M | -16% | 95k | 1320.83 |
|
| Mirum Pharmaceuticals (MIRM) | 9.9 | $122M | +4% | 1.3M | 92.38 |
|
| Maplight Therapeutics (MPLT) | 6.1 | $75M | 3.7M | 20.33 |
|
|
| salesforce (CRM) | 5.9 | $73M | +19% | 393k | 186.67 |
|
| Crinetics Pharmaceuticals In (CRNX) | 4.6 | $56M | -4% | 1.6M | 36.32 |
|
| Enliven Therapeutics (ELVN) | 4.1 | $50M | -13% | 1.3M | 39.20 |
|
| Vaxcyte (PCVX) | 4.0 | $50M | -6% | 860k | 58.11 |
|
| Pharvaris N V (PHVS) | 4.0 | $49M | 1.8M | 28.25 |
|
|
| Arrivent Biopharma (AVBP) | 3.6 | $45M | 1.9M | 23.07 |
|
|
| Miragen Therapeutics (VRDN) | 3.2 | $39M | -15% | 2.0M | 19.56 |
|
| Celldex Therapeutics Com New (CLDX) | 3.1 | $38M | 1.2M | 31.72 |
|
|
| Apogee Therapeutics (APGE) | 3.1 | $38M | -21% | 450k | 84.17 |
|
| BioMarin Pharmaceutical (BMRN) | 3.0 | $37M | 660k | 56.49 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 2.8 | $34M | 3.7M | 9.31 |
|
|
| Alibaba Group Hldg Sponsored Ads (BABA) | 2.6 | $32M | 257k | 125.46 |
|
|
| Xenon Pharmaceuticals (XENE) | 2.3 | $28M | NEW | 485k | 58.15 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 1.6 | $20M | +11% | 2.2M | 8.95 |
|
| Valneva Se Sponsored Ads (VALN) | 0.5 | $6.6M | -54% | 1.1M | 6.25 |
|
| Lanzatech Global Com New (LNZA) | 0.2 | $2.5M | 158k | 16.01 |
|
|
| Marqeta Class A Com (MQ) | 0.1 | $1.8M | 442k | 4.08 |
|
Past Filings by Novo Holdings A/S
SEC 13F filings are viewable for Novo Holdings A/S going back to 2014
- Novo Holdings A/S 2026 Q1 filed May 15, 2026
- Novo Holdings A/S 2025 Q4 filed Feb. 17, 2026
- Novo Holdings A/S 2025 Q3 filed Nov. 14, 2025
- Novo Holdings A/S 2025 Q2 filed Aug. 14, 2025
- Novo Holdings A/S 2025 Q1 filed May 15, 2025
- Novo Holdings A/S 2024 Q4 filed Feb. 14, 2025
- Novo Holdings A/S 2024 Q3 filed Oct. 24, 2024
- Novo Holdings A/S 2024 Q2 restated filed Aug. 20, 2024
- Novo Holdings A/S 2024 Q1 filed May 15, 2024
- Novo Holdings A/S 2023 Q4 filed Feb. 14, 2024
- Novo Holdings A/S 2023 Q3 filed Nov. 14, 2023
- Novo Holdings A/S 2023 Q2 filed Aug. 14, 2023
- Novo Holdings A/S 2023 Q1 filed May 15, 2023
- Novo Holdings A/S 2022 Q4 filed Feb. 14, 2023
- Novo Holdings A/S 2022 Q3 filed Nov. 14, 2022
- Novo Holdings A/S 2022 Q2 filed Aug. 15, 2022